Beyond Ventures

  • Home
  • Beyond Ventures
Website Contact the business

Beyond Ventures A Hong Kong-based venture capital firm aiming at revitalizing HK’s start-up ecosystem

𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 warmly congratulates the Hong Kong Investment Corporation Limited (HKIC) on releasing its highly encoura...
17/07/2026

𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 warmly congratulates the Hong Kong Investment Corporation Limited (HKIC) on releasing its highly encouraging 2025 Annual Report! The report reveals that in 2025, the HKIC recorded a total of investment income of over HK$6.4 billion while its cumulative projects expanded to more than 200 as of the end of June 2026. The HKIC is showcasing the true power of strategic "patient capital". We are honoured to partner with the HKIC to support world-class ophthalmic healthcare flagship projects and help premier life science enterprises leverage Hong Kong’s strengths as a "Super Connector" and "Super Value-Adder", providing a powerful springboard to global markets.

We are incredibly proud to see our two co-invested life science projects, Super Vision and MingMed featured as the selected investment stories in the annual report. Bringing life-changing therapies to market is a marathon that tests endurance and expertise, and these clinical breakthroughs perfectly validate the strategic resolve and profound industry insights of our joint investment teams.

• Super Vision developed i-NYS, the world’s first Class III active implantable device for congenital nystagmus, bringing hope to over 7 million patients worldwide. Backed by the HKIC and Beyond Ventures, Super Vision secured a US FDA HUD designation and is using Hong Kong as a springboard for US clinical trials. The Company is also pioneering visual Brain-Computer Interface (BCI) technology (NeuraVision) to restore sight, aligning with the National 15th Five-Year Plan.

• MingMed achieved a major milestone progress with QA102, a first-in-class oral drug for Dry AMD (the world's third leading cause of blindness). Its promising Phase II clinical data was showcased in a dedicated session at the prestigious ARVO meeting. Leveraging the patient capital, MingMed is laying the groundwork for subsequent Phase III clinical design and dosage optimization, as well as potential out-licensing/collaboration opportunities while kick-starting R&D collaborations with multiple Hong Kong universities.

We look forward to continuing to walk shoulder-to-shoulder with the HKIC. Together, we will continue utilizing this unique two-way channel between premier mainland tech enterprises and Hong Kong's I&T ecosystem to nurture world-class innovations and consolidate Hong Kong's position as a premier global hub for technology and life sciences!

For more information about this news, please refer to this link
https://bit.ly/4f91V24

𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 is delighted to announce that two of our portfolio companies were honored at the prestigious 2025 Deloit...
26/03/2026

𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 is delighted to announce that two of our portfolio companies were honored at the prestigious 2025 Deloitte Greater Bay Area Technology Fast Program, held on March 26, 2026.

𝐌𝐢𝐧𝐠𝐌𝐞𝐝, a biotech company dedicated to the in house discovery and development of first in class drugs addressing global unmet medical needs, has built a diverse pipeline spanning ophthalmic therapies, recombinant botulinum toxin, immuno oncology, and pet immune drugs.

Another winning company, 𝟎𝟏 𝐋𝐢𝐟𝐞, is a pioneering biotech firm focused on developing and commercializing advanced liquid biopsy technologies for cancer early detection and continuous monitoring, empowering clinicians with non invasive, real time insights into patient health.

We extend our heartfelt congratulations to these exceptional companies recognized as part of the 2025 Deloitte GBA Fast 40, celebrating their remarkable founding teams, visionary leadership, and ability to transform groundbreaking research and development into commercially viable solutions.

As one of the capital partners of the Awards Program, Beyond Ventures was honored to have our Senior Vice President, Ms. Floria Chan, in attendance to witness these memorable moments and share the joy with Ms. Liza Ko, CFO of MingMed, and Ms. Meixi Chen, Chief Business Officer of 01 Life, who proudly represented their companies in receiving the awards and celebrating the region’s next generation of unicorns.

We look forward to continuing our mission of empowering visionary founders and advancing groundbreaking technologies that shape the future of healthcare and beyond. At Beyond Ventures, we remain committed to supporting innovation that transforms lives and strengthens Hong Kong’s role as a hub for world class AI and technology excellence.


𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 is proud to have participated in Jumpstarter 2026, Asia’s leading startup and tech event held on March 1...
26/03/2026

𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 is proud to have participated in Jumpstarter 2026, Asia’s leading startup and tech event held on March 12–13, 2026.

Our Investment Team members, James Chan, Associate Investment Director and Sharon Wang, Investment Manager, contributed as semi-finalist judges in the Global Startup Competition, helping select the top 30 finalists from an outstanding pool of startups.

The highlight of the event was our 𝐂𝐨-𝐟𝐨𝐮𝐧𝐝𝐞𝐫 𝐚𝐧𝐝 𝐌𝐚𝐧𝐚𝐠𝐢𝐧𝐠 𝐏𝐚𝐫𝐭𝐧𝐞𝐫, 𝐋𝐚𝐩 𝐌𝐚𝐧, who joined the panel discussion “Beyond the Chip: Investing in the Physical Backbone of AI.” With over 25 years of experience in managing networks and data centers, Lap Man shared valuable insights into why global giants are building AI data centers in Southeast Asia. He also explained how data center location strategies have evolved over time, shifting from prioritizing proximity to users towards leveraging state of the art, long distance, high speed connectivity.

His perspectives resonated strongly with the audience, sparking lively discussions and leaving participants inspired by his insights and forward-looking vision.

At Beyond Ventures, we remain committed to empowering startups and driving transformative growth across the region and beyond.

As a strategic investment partner of the Hong Kong Investment Corporation (HKIC) since 2024, 𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 welcomes th...
03/03/2026

As a strategic investment partner of the Hong Kong Investment Corporation (HKIC) since 2024, 𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 welcomes the new initiatives outlined in the 2026-27 Budget. We commend the HKIC's pivotal role in orchestrating synergy across the HKSAR Government, industry, academia, research, and investment sectors, building a more integrated and dynamic innovation ecosystem. What distinguishes the HKIC is that it combines the role of a traditional profit-seeking fund and a strategic governmental fund perfectly. While the HKIC is market-oriented and industry-focused, it is also a globally connected patient capital partner. By deploying capital strategically, the HKIC not only supports high-flying individual enterprises, but also catalyzes broader industrial development and strengthens Hong Kong's capital markets. In doing so, it reinforces Hong Kong's enduring competitiveness as a global hub for investment, technology, and entrepreneurship, bridging China and the world with credibility and foresight.

Over the past two years, it has been our privilege to collaborate closely with the HKIC, co-investing in a number of high-potential ventures across hardcore technology, biotech, and new energy/greentech. From early-stage Hong Kong universities’ startups to late-stage worldwide leading companies landing in Hong Kong. These investments span Hong Kong, Mainland China, and the rest of the world, with strong founding teams, significant revenue potential, global ambition and they further enhance Hong Kong innovation and technology ecosystems.

In response to the 2026-27 Budget, Beyond Ventures is thrilled to see that the HKIC has invested in over 190 projects spanning the above-mentioned sectors. We welcome the HKSAR Government’s continued commitment to innovation, covering industries such as biotech, AI, and new energy/greentech, sectors that are the focus of both the HKIC and Beyond Ventures. The proposed establishment of the Committee on AI+ and Industry Development Strategy with an initial focus on life and health technology and embodied AI, is conducive to formulating strategies and creating favorable policies for AI to empower the transformation and development of these industries.

Looking ahead, Beyond Ventures remains deeply committed to its long-term partnership with the HKIC. Together, we will continue to back visionary founders, drive technological breakthroughs, and solidify Hong Kong's position as a super-connector and super-value adder in the global tech landscape.

Congratulations to Hong Kong Investment Corporation Limited (HKIC) on its outstanding achievements in its inaugural annu...
12/12/2025

Congratulations to Hong Kong Investment Corporation Limited (HKIC) on its outstanding achievements in its inaugural annual report.

𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 is honored to be a strategic partner of the HKIC. To date, our collaboration has yielded remarkable results. All companies in our investment portfolio have successfully secured or are advancing follow-on investment, with some projects already initiating IPO processes.

Most of these enterprises possess globally leading technologies or applications. At critical moments, the HKIC’s commitment to a "market-oriented operation" model and the principle of "patient capital" played an irreplaceable role: it not only provided these companies with strategic support far beyond capital, helping them overcome challenges from inception and R&D to globalization, but also prevented potential sacrifices of long-term development due to short-term pressures. Moreover, it significantly boosted confidence in the USD venture capital industry across Hong Kong and Chinese Mainland. The HKIC’s successful groundwork has solidified a new, critical position and role for Hong Kong in the landscape of technological innovation within China and globally.

𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬, a Hong Kong-based venture capital firm, is proud to participate in 𝐇𝐊𝐔𝐌𝐞𝐝𝐗𝐞𝐥𝐞𝐫𝐚𝐭𝐞 𝟐𝟎𝟐𝟓, supported by th...
10/12/2025

𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬, a Hong Kong-based venture capital firm, is proud to participate in 𝐇𝐊𝐔𝐌𝐞𝐝𝐗𝐞𝐥𝐞𝐫𝐚𝐭𝐞 𝟐𝟎𝟐𝟓, supported by the HKUMed Tam Wing Fan Innovation Start-up Grant. This pioneering initiative empowers HKUMed project teams to sharpen their concepts and accelerate their path toward commercialization and funding.

From late October through December 2025, HKUMedXelerate 2025 offered a rich lineup of seminars, workshops, a biomedical industry immersion trip to Jiangsu, and a startup competition featuring a final pitch event. These activities enabled HKUMed researchers and founders to refine, elevate, and fast-track their innovative ideas into impactful healthcare solutions, while also creating valuable opportunities to connect with stakeholders across Hong Kong and China’s startup ecosystem.

We were honored to collaborate with our portfolio company MingMed, an innovative biotech firm specializing in first-in-class drug development to support this pioneering initiative by serving as seminar panelists and startup competition judges. The “𝘉𝘪𝘰𝘵𝘦𝘤𝘩 𝘉𝘳𝘦𝘢𝘬𝘵𝘩𝘳𝘰𝘶𝘨𝘩𝘴 – 𝘗𝘰𝘸𝘦𝘳𝘪𝘯𝘨 𝘊𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭𝘪𝘴𝘢𝘵𝘪𝘰𝘯 𝘢𝘯𝘥 𝘞𝘪𝘯𝘯𝘪𝘯𝘨 𝘐𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵” 𝘴𝘦𝘮𝘪𝘯𝘢𝘳, held on November 20, 2025, featured 𝐌𝐫. 𝐋𝐚𝐩 𝐌𝐚𝐧, 𝐂𝐨-𝐟𝐨𝐮𝐧𝐝𝐞𝐫 𝐚𝐧𝐝 𝐌𝐚𝐧𝐚𝐠𝐢𝐧𝐠 𝐏𝐚𝐫𝐭𝐧𝐞𝐫 𝐨𝐟 𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬, alongside Dr. Hui Ouyang, MingMed’s Chief Technology Officer, with Professor Joshua Ho, Assistant Dean (Innovation & Technology Transfer) of HKUMed as a moderator. Together, they shared valuable insights from the perspectives of venture capital and biotech research translation, earning highly positive feedback from the audience.

In addition, Mr. Oliver Chen, our Investment Director, served as one of the preliminary judges in late October, shortlisting 10 finalists from over 60 candidates. Dr. Hui Ouyang later joined the final judging panel, which selected five winners at the final pitch event on December 5, 2025. Each winning team was awarded HK$1.5 million in funding. Together with the other judges, Dr. Hui Ouyang provided invaluable insights and constructive suggestions to all participating project teams.

At Beyond Ventures, we firmly believe that supporting pioneering initiatives like HKUMedXelerate 2025 is a supportive way to empower aspiring researchers and founders. By providing insights, networks, and opportunities, we aim to accelerate their growth journeys and help drive the development of visionary healthcare innovations.

𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 is honored to announce its appointment by the Hong Kong Investment Corporation Limited (HKIC) as 𝐨𝐧𝐞 𝐨𝐟 ...
05/12/2025

𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 is honored to announce its appointment by the Hong Kong Investment Corporation Limited (HKIC) as 𝐨𝐧𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐚𝐬𝐬𝐞𝐭 𝐦𝐚𝐧𝐚𝐠𝐞𝐫𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞 𝟐𝟎𝟐𝟓 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 𝐁𝐚𝐭𝐜𝐡 𝐨𝐟 𝐭𝐡𝐞 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐏𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨 (𝐂𝐈𝐄𝐒 𝐈𝐏) 𝐮𝐧𝐝𝐞𝐫 𝐭𝐡𝐞 𝐍𝐞𝐰 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐄𝐧𝐭𝐫𝐚𝐧𝐭 𝐒𝐜𝐡𝐞𝐦𝐞 (𝐍𝐞𝐰 𝐂𝐈𝐄𝐒).

“We would like to express our gratitude to the HKIC for its continued trust and recognition,” remarked 𝐌𝐫. 𝐋𝐚𝐩 𝐌𝐚𝐧, 𝐂𝐨-𝐟𝐨𝐮𝐧𝐝𝐞𝐫 & 𝐌𝐚𝐧𝐚𝐠𝐢𝐧𝐠 𝐏𝐚𝐫𝐭𝐧𝐞𝐫 𝐨𝐟 𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬. “The New CIES represents a bold and innovative policy initiative that 10% of the capital from the CIES IP be allocated to promote Hong Kong’s innovative & technology (I&T) development. This is not only visionary but also sets a benchmark for how capital can effectively amplify market-driven innovation. It underscores the distinctive strength of Hong Kong’s capital markets by seamlessly integrating government guidance with vibrant market dynamics, a hallmark of the HKIC’s strategic vision.”

The speed and efficiency of the HKIC’s implementation also further reflect the true spirit of Hong Kong. From the issuance of the invitation for proposals on October 31, 2025, to the application deadline on November 14, and the announcement of selected asset managers on December 2, in just 11 working days. The entire process exemplifies how a patient capital institution wholly owned by and representing the HKSAR Government can operate with the agility of a startup. This “Hong Kong speed” is a testament to the city’s world-class governance and ex*****on capabilities. The integration of public and private capital and the unparalleled ex*****on efficiency will be the two cornerstones for Hong Kong’s I&T development.

Beyond Ventures has long been a close partner of the HKIC, having co-invested in multiple projects across hard core, biotech, and new energy/greentech sectors. These collaborations include investments in global industry leaders, chain master enterprises and several highly potential companies preparing for IPOs on the Hong Kong Stock Exchange.

Although Hong Kong has a deep talent pool and a highly international environment that fosters cutting-edge technological research, it lacks extensive industrial applications and market insights due to a relatively small local market. Therefore, getting more chain master or industry-leading corporations to Hong Kong accelerates the integration of local resources with these corporations. This synergy drives the innovation and technology ecosystem which is crucial to Hong Kong’s I&T development and also beneficial to these corporations.

“In alignment with this vision, Beyond Ventures will deploy its assigned capital from the 2025 Capital Batch of the CIES IP in close collaboration with the HKIC and the leading and chain master enterprises within the HKIC ecosystem. By forging strategic partnerships with these anchor players, Beyond Ventures aims to strengthen Hong Kong’s dual role as a “super connector” and a “super value-adder” in the global innovation landscape. We will collaborate with the HKIC and its ecosystem partners to inject vitality into Hong Kong's I&T ecosystem.” Mr. Lap Man added.

We are pleased to share that our Co-founder and Managing Partner Lap Man, alongside Venture Partner Susan Hu and SVP Flo...
30/09/2025

We are pleased to share that our Co-founder and Managing Partner Lap Man, alongside Venture Partner Susan Hu and SVP Floria Chan, attended the inaugural 𝐁𝐞𝐔𝐧𝐢𝐜𝐨𝐫𝐧 𝐃𝐚𝐲 𝐡𝐨𝐬𝐭𝐞𝐝 𝐛𝐲 𝐇𝐨𝐧𝐠 𝐊𝐨𝐧𝐠 𝐁𝐚𝐩𝐭𝐢𝐬𝐭 𝐔𝐧𝐢𝐯𝐞𝐫𝐬𝐢𝐭𝐲 (𝐇𝐊𝐁𝐔) on 26 Sep 2025, a landmark event celebrating innovation, entrepreneurship, and the launch of HKBU’s new start-up platform, Inno Nexus.

Hosted by the Knowledge Transfer Office (KTO) at HKBU, the event, themed “Be Driven. Be Engaged. Be a Unicorn,” showcased 25 start-ups spanning diverse sectors, including biotech, sustainable energy, digital IP protection, AI-driven solutions, agritech, and social enterprise.

As part of the exciting highlight, 𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 signed a Memorandum of Understanding (MOU) with HKBU to mark a new chapter of strategic partnership and collaboration. Representing Beyond Ventures, Floria Chan signed the MOU, with Lap Man serving as witness. On HKBU’s side, Edmond Lam, Director of the Knowledge Transfer Office, acted as the signer, witnessed by Professor Terence Lau, Interim Chief Innovation Officer, and Mr Paul P**n, Deputy Chairman of the Council and the Court.

This partnership reflects our shared commitment to empowering start-ups, driving innovation, and building bridges between academia and industry. With Inno Nexus now live, we look forward to supporting HKBU’s vibrant start-up ecosystem through mentorship, investment, and collaboration.

Hong Kong-based venture capital firm 𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 proudly champions the 𝐇𝐨𝐧𝐠 𝐊𝐨𝐧𝐠 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐋𝐢𝐦𝐢𝐭𝐞𝐝 (𝐇𝐊𝐈...
18/09/2025

Hong Kong-based venture capital firm 𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 proudly champions the 𝐇𝐨𝐧𝐠 𝐊𝐨𝐧𝐠 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐋𝐢𝐦𝐢𝐭𝐞𝐝 (𝐇𝐊𝐈𝐂)’’s new initiatives outlined in The Policy Address 2025 and its pivotal role in driving innovation and elevating Hong Kong’s position in the global technology arena. This endorsement follows a highly productive year of strategic partnership, resulting in a number of co-investments, each contributing meaningfully to the local economy and innovation ecosystem.

The partnership between Beyond Ventures and the HKIC exemplifies this success. In just over a year, the two companies have co-invested in a number of high-potential ventures spanning their three strategic focus areas, namely hardcore technology, biotech, and new energy/greentech. These include Chinese tech firms establishing a presence in Hong Kong and deep-tech startups spun out from leading local universities such as The Chinese University of Hong Kong and The Hong Kong University of Science and Technology. Notably, two of these companies have already submitted or are preparing to submit IPO applications to the Hong Kong Stock Exchange (HKEX).

In response to the 2025 Policy Address, Beyond Ventures welcomes the HKSAR Government’s continued commitment to innovation, particularly in biotech, AI, and new energy, sectors that are the focus of the HKIC and Beyond Ventures’ partnership. The proposed establishment of the International Clinical Trial Academy and the Hong Kong Centre for Medical Products Regulation is a timely and strategic move to strengthen the biotech ecosystem. These initiatives will help cultivate clinical trial talent and attract global pharmaceutical companies to accelerate their launch of innovative drugs in Hong Kong.

At the same time, the Government’s strong emphasis on AI, driven by the dual vision of “industries for AI” and “AI for industries” is expected to attract a new wave of startups and talent, further positioning Hong Kong as a global innovation powerhouse.

“The HKIC’s role as Hong Kong’s “patient capital” has been truly transformative. Our strategic partnership has enabled us to support startups that now form the backbone of Hong Kong’s innovation ecosystem. We fully endorse the HKIC’s expanded mandate, including its cross-border collaboration with the Guangdong Government to accelerate biotech development, and its forward-looking investments in frontier industries such as commercial aerospace and the space economy. Together, we are reinforcing Hong Kong’s position as a global super-connector and a powerful value-adder in the tech landscape.” said 𝐋𝐚𝐩 𝐌𝐚𝐧, 𝐂𝐨-𝐟𝐨𝐮𝐧𝐝𝐞𝐫 & 𝐌𝐚𝐧𝐚𝐠𝐢𝐧𝐠 𝐏𝐚𝐫𝐭𝐧𝐞𝐫 𝐨𝐟 𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬.

Looking ahead, Beyond Ventures and the HKIC remain committed to a long-term, fruitful partnership. This collaboration will continue to focus on strengthening Hong Kong’s role in cross-border innovation and expanding its capacity as a global hub that connects international markets, delivers enterprise value, and energizes the industry.

#𝐁𝐞𝐲𝐨𝐧𝐝𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 #𝐋𝐚𝐩𝐌𝐚𝐧 #𝐇𝐊𝐈𝐂 #𝐂𝐥𝐚𝐫𝐚𝐂𝐡𝐚𝐧 #𝐓𝐡𝐞𝐏𝐨𝐥𝐢𝐜𝐲𝐀𝐝𝐝𝐫𝐞𝐬𝐬𝟐𝟎𝟐𝟓 #𝐒𝐭𝐚𝐫𝐭𝐮𝐩𝐬 #𝐂𝐡𝐢𝐞𝐟𝐄𝐱𝐞𝐜𝐮𝐭𝐢𝐯𝐞

𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬, a Hong Kong-based venture capital firm, was honored to have 𝐋𝐚𝐩 𝐌𝐚𝐧, 𝐂𝐨-𝐟𝐨𝐮𝐧𝐝𝐞𝐫 & 𝐌𝐚𝐧𝐚𝐠𝐢𝐧𝐠 𝐏𝐚𝐫𝐭𝐧𝐞𝐫, par...
02/04/2025

𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬, a Hong Kong-based venture capital firm, was honored to have 𝐋𝐚𝐩 𝐌𝐚𝐧, 𝐂𝐨-𝐟𝐨𝐮𝐧𝐝𝐞𝐫 & 𝐌𝐚𝐧𝐚𝐠𝐢𝐧𝐠 𝐏𝐚𝐫𝐭𝐧𝐞𝐫, participate in the panel discussion “Unlocking Potential: Insights from Investment Leads” while 𝐏𝐫𝐨𝐟𝐞𝐬𝐬𝐨𝐫 𝐅𝐫𝐚𝐧𝐜𝐢𝐬 𝐂𝐡𝐚𝐧, Former Dean of the Faculty of Medicine at CUHK, Steering Committee Member of RAISe+, and 𝐚 𝐤𝐞𝐲 𝐜𝐨𝐧𝐭𝐫𝐢𝐛𝐮𝐭𝐨𝐫 𝐭𝐨 𝐆-𝐍𝐢𝐢𝐛 𝐆𝐞𝐧𝐢𝐞𝐁𝐢𝐨𝐦𝐞—𝐨𝐧𝐞 𝐨𝐟 𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬' 𝐩𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬, joined another insightful panel discussion, “From Lab to Market: Insights on RAISe+ Application” in the 𝐂𝐔𝐇𝐊 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐒𝐮𝐦𝐦𝐢𝐭 𝟐𝟎𝟐𝟓 held on March 31, 2025.

The annual flagship investor event organized by CUHK Innovation serves as a vital platform for fostering collaboration among investors, industry leaders, and academics within Hong Kong's dynamic startup ecosystem. During their discussions, Lap Man and Professor Chan shared invaluable insights and experiences from their respective perspectives—as an investor and a Steering Committee member of RAISe+—offering practical guidance specifically tailored to RAISe+ startup project teams.

At 𝐁𝐞𝐲𝐨𝐧𝐝 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬, we firmly believe that supporting events like the CUHK Innovation Summit is an ideal way to empower aspiring entrepreneurs by providing them with valuable insights, networks, and opportunities to drive their growth journeys.

#𝐁𝐞𝐲𝐨𝐧𝐝𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 #𝐋𝐚𝐩𝐌𝐚𝐧 #𝐆𝐍𝐢𝐢𝐁𝐆𝐞𝐧𝐢𝐞𝐁𝐢𝐨𝐦𝐞 #𝐏𝐫𝐨𝐟𝐞𝐬𝐬𝐨𝐫𝐅𝐫𝐚𝐧𝐜𝐢𝐬𝐂𝐡𝐚𝐧 #𝐂𝐔𝐇𝐊 #𝐂𝐔𝐇𝐊𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 #𝐄𝐧𝐭𝐫𝐞𝐩𝐫𝐞𝐧𝐞𝐮𝐫𝐬𝐡𝐢𝐩 #𝐑𝐀𝐈𝐒𝐄+

Address


Alerts

Be the first to know and let us send you an email when Beyond Ventures posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Beyond Ventures:

Shortcuts

  • Want your business to be the top-listed health & beauty business?

Share